Barigen 4 mg is a tablet containing 4 mg of baricitinib, a Janus kinase (JAK) inhibitor. It is a prescription medicine and should be used under the direction of a qualified healthcare professional.

Baricitinib is an oral JAK inhibitor that reduces signaling through selected inflammatory pathways. It modifies immune-system activity and is used for certain authorized inflammatory and immune-related conditions.

The approved uses of baricitinib depend on the country and indication. Baricitinib is used in selected patients with conditions such as rheumatoid arthritis and severe alopecia areata, as well as other authorized conditions in certain jurisdictions. Always follow the indication approved by your local regulatory authority.

Barigen and Olumiant are different branded products. Both may contain the active ingredient baricitinib, but their manufacturers, packaging, regulatory authorization and availability may differ by country.

Not universally. The appropriate baricitinib dose depends on the condition being treated, the patient's age, kidney function, other medical factors and local prescribing information. Do not change the dose without medical advice.

Baricitinib may generally be taken with or without food according to current prescribing information. Take Barigen exactly as directed by your healthcare professional.

No. Baricitinib is not a corticosteroid. It is a Janus kinase (JAK) inhibitor that works by modifying signaling involved in immune and inflammatory responses.

Yes. Baricitinib modifies immune-system signaling and can reduce certain immune and inflammatory responses. Because of this effect, it can increase the risk of infections and requires appropriate medical monitoring.

Reported side effects can include upper respiratory infections, headache, nausea, acne, changes in cholesterol levels and laboratory abnormalities. The exact adverse-effect profile can vary depending on the indication and individual patient.

Yes. Baricitinib can increase the risk of infections, including serious infections such as tuberculosis and opportunistic infections. Patients should discuss their infection history and risk factors with their healthcare professional before and during treatment.

Thrombosis, including blood clots in veins and arteries, has been reported with baricitinib. The risk should be discussed with a healthcare professional, particularly in patients with other risk factors for blood clots.

JAK inhibitors, including baricitinib, carry important cardiovascular safety warnings. Your healthcare professional can assess your individual cardiovascular risk and determine whether baricitinib is appropriate for you.

Malignancies have occurred in patients treated with baricitinib. Important warnings apply to JAK inhibitors regarding malignancy risk. Discuss your individual risk factors and treatment options with your healthcare professional.

Baricitinib is authorized for the treatment of severe alopecia areata in certain patients. Approval and age eligibility differ between countries, so treatment should follow the applicable local prescribing information.

Baricitinib is authorized for certain patients with atopic dermatitis in some jurisdictions, including the European Union. Regulatory authorization differs between countries. A healthcare professional should determine whether it is appropriate for a particular patient.

Age eligibility depends on the indication and country. Some jurisdictions authorize baricitinib for certain pediatric uses, while other regulatory approvals may focus on adults. Children should only receive baricitinib when specifically prescribed by an appropriate healthcare professional.

Combining baricitinib with another JAK inhibitor is generally not recommended under current U.S. prescribing information. Tell your healthcare professional about all medicines you are taking before starting treatment.

Yes. Medical monitoring may include blood counts, liver enzymes, cholesterol or lipid testing and other assessments depending on the patient's condition and treatment. Your healthcare professional will determine which tests are appropriate.

For certain indications, tuberculosis evaluation is recommended before starting baricitinib and monitoring may be required during treatment. Your healthcare professional will determine the appropriate screening based on your medical history and local prescribing information.

Pregnancy should be discussed with your healthcare professional before using baricitinib. Regulatory information identifies potential fetal risks, and treatment during pregnancy should only occur when specifically considered appropriate by the treating healthcare professional.

Breastfeeding recommendations vary according to applicable prescribing information. Current U.S. prescribing information advises against breastfeeding during treatment with baricitinib. Discuss breastfeeding and treatment options with your healthcare professional.

The Barigen product described on this website is identified as a 4 mg tablet. Baricitinib itself is available in different strengths depending on the product and jurisdiction. Availability should be confirmed from the specific product packaging and local product information.

No. Do not change your baricitinib dose yourself. The appropriate dose depends on your medical condition and other factors. Any dose adjustment should be made by the prescribing healthcare professional.

Store Barigen according to the storage instructions printed on the specific product packaging and applicable local product information. Keep medicines out of reach of children and do not use the product after its stated expiry date.